Cargando…

Severe COVID-19 Illness and α1-Antitrypsin Deficiency: COVID-AATD Study

Background: Epidemiologic studies have reported that the geographical distribution of the prevalence of allelic variants of serine protein inhibitor-A1 (SERPINA1) and severe cases of COVID-19 were similar. Methods: A multicenter, cross-sectional, observational study to evaluate the frequency of alph...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez Hermosa, Juan Luis, Vargas Centanaro, Gianna, González Castro, María Estela, Miravitlles, Marc, Lázaro-Asegurado, Lourdes, Jiménez-Rodríguez, Beatriz María, Rodríguez, Rosanel Amaro, Moreno Méndez, Rosaly, Torres-Duran, María, Hernández-Pérez, José María, Humanes-Navarro, Ana María, Calle Rubio, Myriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953718/
https://www.ncbi.nlm.nih.gov/pubmed/36831051
http://dx.doi.org/10.3390/biomedicines11020516
Descripción
Sumario:Background: Epidemiologic studies have reported that the geographical distribution of the prevalence of allelic variants of serine protein inhibitor-A1 (SERPINA1) and severe cases of COVID-19 were similar. Methods: A multicenter, cross-sectional, observational study to evaluate the frequency of alpha-1 antitrypsin deficiency (AATD) in patients with COVID-19 and whether it was associated with having suffered severe COVID-19. Results: 2022 patients who had laboratory-confirmed SARS-CoV-2 infection. Mutations associated with AATD were more frequent in severe COVID versus non-severe (23% vs. 18.8%, p = 0.022). The frequency of Pi*Z was 37.8/1000 in severe COVID versus 17.5/1000 in non-severe, p = 0.001. Having an A1AT level below 116 was more frequent in severe COVID versus non-severe (29.5% vs. 23.1, p = 0.003). Factors associated with a higher likelihood of severe COVID-19 were being male, older, smoking, age-associated comorbidities, and having an A1AT level below 116 mg/dL [OR 1.398, p = 0.003], and a variant of the SERPINA1 gene that could affect A1AT protein [OR 1.294, p = 0.022]. Conclusions: These observations suggest that patients with AATD should be considered at a higher risk of developing severe COVID-19. Further studies are needed on the role of A1AT in the prognosis of SARS-CoV-2 infection and its possible therapeutic role.